Nature Search

T_SCM-predominant allogeneic anti-BCMA CAR-T therapy for relapsed/refractory multiple myeloma: preclinical characterization and interim results from a phase 1 trial

CAR-T cell therapy has been shown to be effective in immunotherapy for treatment of several different tumours. Here the authors show pre-specified interim outcomes from a P-BCMA-ALLO1 trial with BCMA targeted CAR-T therapy in multiple myeloma.

Hubert Tseng
Bhagirathbhai Dholaria
Devon J. Shedlock
ResearchOpen Access24 Nov 2025
Nature Communications

Volume: 16, P: 1-14
Comprehensive characterization of RAS mutations in colon and rectal cancers in old and young patients

Activating oncogenic mutations in KRAS and NRAS are common in colorectal cancer, which is a heterogenous disease. Here, the authors show that the RAS mutation spectrum is markedly different between colon and rectal cancer, and also different based on age of diagnosis and microsatellite instability.

Ilya G. Serebriiskii
Caitlin Connelly
Joshua E. Meyer
ResearchOpen Access19 Aug 2019
Nature Communications

Volume: 10, P: 1-12
Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial

In the first-in-human trial of elranatamab, patients with refractory or relapsed multiple myeloma who received the bispecific antibody against BCMA and CD3 experienced no dose-limiting toxicities during dose escalation, and the agent showed promising clinical efficacy.

Nizar J. Bahlis
Caitlin L. Costello
Alexander M. Lesokhin
ResearchOpen Access02 Oct 2023
Nature Medicine

Volume: 29, P: 2570-2576
Alu-dependent RNA editing of GLI1 promotes malignant regeneration in multiple myeloma

The treatment of multiple myeloma is challenging due to high relapse rates. Here the authors show that expression of ADAR1 correlates with poor patient outcomes, and that ADAR1-mediated editing of GLI1 is a mechanism relevant in the context of multiple myeloma progression and drug resistance.

Elisa Lazzari
Phoebe K. Mondala
Catriona H. M. Jamieson
ResearchOpen Access04 Dec 2017
Nature Communications

Volume: 8, P: 1-10
Comprehensive molecular profiling of multiple myeloma identifies refined copy number and expression subtypes

Longitudinal genomic and transcriptomic profiling of 1,143 patients with multiple myeloma by the Relating Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profile study yields an improved copy number and gene expression subtype scheme, most notably a high-risk proliferative subtype associated with complete loss of RB1 or MAX.

Sheri Skerget
Daniel Penaherrera
Jonathan J. Keats
ResearchOpen Access19 Aug 2024
Nature Genetics

Volume: 56, P: 1878-1889
Author Correction: Comprehensive molecular profiling of multiple myeloma identifies refined copy number and expression subtypes

Sheri Skerget
Daniel Penaherrera
Jonathan J. Keats
Amendments and CorrectionsOpen Access09 Jun 2025
Nature Genetics

Volume: 57, P: 1789
Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk

Natalie S. Callander
Rebecca Silbermann
Peter M. Voorhees
ResearchOpen Access22 Apr 2024
Blood Cancer Journal

Volume: 14, P: 1-8
Daratumumab in transplant-eligible patients with newly diagnosed multiple myeloma: final analysis of clinically relevant subgroups in GRIFFIN

Ajai Chari
Jonathan L. Kaufman
Paul G. Richardson
ResearchOpen Access08 Jul 2024
Blood Cancer Journal

Volume: 14, P: 1-10
Use of term reference infants in assessing the developmental outcome of extremely preterm infants: lessons learned in a multicenter study

Charles E. Green
Jon E. Tyson
Kimberlee Weaver-Lewis
ResearchOpen Access04 Aug 2023
Journal of Perinatology

Volume: 43, P: 1398-1405
Assembly of the Caenorhabditis elegans gut microbiota from diverse soil microbial environments

Maureen Berg
Ben Stenuit
Michael Shapira
ResearchOpen Access22 Jan 2016
The ISME Journal

Volume: 10, P: 1998-2009
Single dose of a replication-defective vaccinia virus expressing Zika virus-like particles is protective in mice

Brittany Jasperse
Caitlin M. O’Connell
Paulo H. Verardi
ResearchOpen Access22 Mar 2021
Scientific Reports

Volume: 11, P: 1-14
Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of life

Evangelos Terpos
Joseph Mikhael
Saad Z. Usmani
ReviewsOpen Access18 Feb 2021
Blood Cancer Journal

Volume: 11, P: 1-13

Search

T_SCM-predominant allogeneic anti-BCMA CAR-T therapy for relapsed/refractory multiple myeloma: preclinical characterization and interim results from a phase 1 trial

Comprehensive characterization of RAS mutations in colon and rectal cancers in old and young patients

Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial

Alu-dependent RNA editing of GLI1 promotes malignant regeneration in multiple myeloma

Comprehensive molecular profiling of multiple myeloma identifies refined copy number and expression subtypes

Author Correction: Comprehensive molecular profiling of multiple myeloma identifies refined copy number and expression subtypes

Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk

Daratumumab in transplant-eligible patients with newly diagnosed multiple myeloma: final analysis of clinically relevant subgroups in GRIFFIN

Use of term reference infants in assessing the developmental outcome of extremely preterm infants: lessons learned in a multicenter study

Assembly of the Caenorhabditis elegans gut microbiota from diverse soil microbial environments

Single dose of a replication-defective vaccinia virus expressing Zika virus-like particles is protective in mice

Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of life

Search

Quick links

Search

Filter By:

Search

Quick links